Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus HYDELTRASOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus HYDELTRASOL.
BREO ELLIPTA vs HYDELTRASOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Corticosteroid